<DOC>
	<DOCNO>NCT02587221</DOCNO>
	<brief_summary>A Phase III , Randomized , Observer-Blind , Controlled , Multicenter Clinical Study Evaluate Efficacy , Safety Immunogenicity MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared Non-influenza Vaccine Comparator Adults ≥ 65 Years Age .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy , Safety Immunogenicity MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared Non-influenza Vaccine Comparator Adults ≥ 65 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>1 . Males females ≥ 65 year old healthy comorbidities 2 . Individuals whose legal guardian voluntarily give write consent nature study explain accord local regulatory requirement , prior study entry . 3 . Ability attend schedule visit comply study procedure 1 . Hypersensitivity , include allergy component vaccine foresee study 2 . Abnormal function immune system . 3 . Receipt influenza vaccine within 6 month prior enrolment study plan receive influenza vaccine participate study . 4 . Additional eligibility criterion may discuss contact site</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>